July 4 - 5, 2019

Dear collegues, 

Stereotactic ablative body radiotherapy (SABR) is now an essential aspect of modern multidisciplinary cancer care. With the results of SABR-COMET and other randomized trials emerging, more national guidelines are expected to incorporate SABR as a treatment option, making knowledge and availability of SABR essential for all radiation oncologists.

The clinical use of adaptive radiotherapy has also increased markedly in the past 3 years, both with and without guidance using on table MR imaging. Emerging data from on-table, adaptive SABR delivery since 2016 has revealed meaningful benefits in selected patient groups, which in turn requires other departments to formulate their own strategies for implementing adaptive radiotherapy.

The faculty for this symposium includes national and international experts who have both extensive clinical experience, and who are leading key trials in this field. At this meeting, all sessions and talks will be geared towards the practical aspects of SABR, as well as adaptive radiotherapy for some non-SABR indications. Formal talks will emphasize a structured approach for patient selection, planning and delivery of suitable patients. Practice-oriented case discussions will allow for interactive discussions illustrating low- and high-risk scenarios. For each clinical case, choice of pre-treatment imaging, treatment planning constraints, delivery techniques, and in-room imaging will be highlighted.

This symposium is designed for clinicians, physicists and radiotherapy technologists who are either setting up a stereotactic program, those which to have an update on this fast-changing field, and those who wish to implement complex, adaptive SABR. The practical nature of the course will also benefit residents, physicists-in-training and employees of health-care firms.

We look forward to welcoming you as a participant and/or sponsor to this symposium in Amsterdam, a city which has the highest museum density in the world and is home to many cultural highlights!

Yours sincerely,

Ben Slotman
Professor and Chair of Radiation Oncology

 Amsterdam UMC